The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients with metastatic kidney cancer.
Patient followed for metastatic clear cell renal cell carcinoma.
Age ≥18 years old.
Performance Status (PS) according to Eastern Cooperative Oncology Group (ECOG) = 0, 1 or 2
Patient treated with a VEGF-R inhibitor: pazopanib or cabozantinib for metastatic kidney cancer.
Indication other than clear cell renal cell carcinoma for these same ITKs
Pregnant or breast-feeding subjects
Patient whose regular follow-up is impossible for psychological, family, social or geographic reasons,
Patient under guardianship, curatorship or safeguard of justice
6
Treatment groupsSee each treatment group below.
Institut du Cancer de Montpellier - Val d'Aurelle
Lead sponsor
Ligue contre le cancer, France
Collaborator